Cargando…
3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs
OBJECTIVES/SPECIFIC AIMS: The goals of this study were (1) to evaluate the effect of proarrhythmic drugs on calcium transient and (2) to use three-dimensional human engineered cardiac tissue (hECT) technology to evaluate cardiac contractile properties in response to pharmacological challenge with pr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799095/ http://dx.doi.org/10.1017/cts.2019.23 |
_version_ | 1783460208424517632 |
---|---|
author | Stillitano, Francesca Turnbull, Irene C. Dave, Jaydev Hulot, Jean-Sébastien Hajjar, Roger J. |
author_facet | Stillitano, Francesca Turnbull, Irene C. Dave, Jaydev Hulot, Jean-Sébastien Hajjar, Roger J. |
author_sort | Stillitano, Francesca |
collection | PubMed |
description | OBJECTIVES/SPECIFIC AIMS: The goals of this study were (1) to evaluate the effect of proarrhythmic drugs on calcium transient and (2) to use three-dimensional human engineered cardiac tissue (hECT) technology to evaluate cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs. METHODS/STUDY POPULATION: Calcium transient was measured in subject-specific iPSC-CMs by using the IonOptix system in Sotalol treated vs. untreated conditions. We fabricated human engineered cardiac tissues (hECT) in a custom designed bioreactor using low- and high-sentitive subject-specific iPSC-CMs. Contractile function of the hECT was evaluated at baseline and after Sotalol [300 µM] administration. The change in beat rate was recorded under spontaneous beating conditions; changes in other twitch parameters, including time to relaxation, were recorded under electrical stimulation. Time to relaxation served as an indicator of action potential duration (APD), which has a temporal correlation with the QT interval. RESULTS/ANTICIPATED RESULTS: The low-sensitive iPSC-CM showed a considerable drop in overall peak height of the calcium transient, in the presence of 100 µM Sotalol. The high-sensitive line, however, showed a more pronounced drop in peak height. Sotalol treatment also induced a more pronounced increase in the exponential decay time constant (tau) in the high-sensitive line compared to the low-sensitive line. The hECT fabricated with high sensitive hiPSC-CM showed a larger decrease in spontaneous beat rate in response to Sotalol (0.41 vs 0.23 fold decrease), with a higher increase in time to relaxation (1.8 vs 1.3 fold increase), compared to hECT from low sensitive hiPSC-CM. Moreover, while the low-sensitive hECT showed a positive correlation between time to relaxation and developed force, as expected after Sotalol stimulation; the high-sensitive hECT failed to show a positive inotropic response. DISCUSSION/SIGNIFICANCE OF IMPACT: Our findings suggest subject-specific iPSC-CMs and hECT, can be used to model functional abnormalities observed in diLQTS in response to Sotalol, and offer novel insights into human-based screening assays for toxic drug reactions. Success of this study may help identify key components underlying diLQT susceptibility to ultimately develop novel therapeutic agents. |
format | Online Article Text |
id | pubmed-6799095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-67990952019-10-28 3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs Stillitano, Francesca Turnbull, Irene C. Dave, Jaydev Hulot, Jean-Sébastien Hajjar, Roger J. J Clin Transl Sci Basic/Translational Science/Team Science OBJECTIVES/SPECIFIC AIMS: The goals of this study were (1) to evaluate the effect of proarrhythmic drugs on calcium transient and (2) to use three-dimensional human engineered cardiac tissue (hECT) technology to evaluate cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs. METHODS/STUDY POPULATION: Calcium transient was measured in subject-specific iPSC-CMs by using the IonOptix system in Sotalol treated vs. untreated conditions. We fabricated human engineered cardiac tissues (hECT) in a custom designed bioreactor using low- and high-sentitive subject-specific iPSC-CMs. Contractile function of the hECT was evaluated at baseline and after Sotalol [300 µM] administration. The change in beat rate was recorded under spontaneous beating conditions; changes in other twitch parameters, including time to relaxation, were recorded under electrical stimulation. Time to relaxation served as an indicator of action potential duration (APD), which has a temporal correlation with the QT interval. RESULTS/ANTICIPATED RESULTS: The low-sensitive iPSC-CM showed a considerable drop in overall peak height of the calcium transient, in the presence of 100 µM Sotalol. The high-sensitive line, however, showed a more pronounced drop in peak height. Sotalol treatment also induced a more pronounced increase in the exponential decay time constant (tau) in the high-sensitive line compared to the low-sensitive line. The hECT fabricated with high sensitive hiPSC-CM showed a larger decrease in spontaneous beat rate in response to Sotalol (0.41 vs 0.23 fold decrease), with a higher increase in time to relaxation (1.8 vs 1.3 fold increase), compared to hECT from low sensitive hiPSC-CM. Moreover, while the low-sensitive hECT showed a positive correlation between time to relaxation and developed force, as expected after Sotalol stimulation; the high-sensitive hECT failed to show a positive inotropic response. DISCUSSION/SIGNIFICANCE OF IMPACT: Our findings suggest subject-specific iPSC-CMs and hECT, can be used to model functional abnormalities observed in diLQTS in response to Sotalol, and offer novel insights into human-based screening assays for toxic drug reactions. Success of this study may help identify key components underlying diLQT susceptibility to ultimately develop novel therapeutic agents. Cambridge University Press 2019-03-27 /pmc/articles/PMC6799095/ http://dx.doi.org/10.1017/cts.2019.23 Text en © The Association for Clinical and Translational Science 2019 http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-ncnd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work. |
spellingShingle | Basic/Translational Science/Team Science Stillitano, Francesca Turnbull, Irene C. Dave, Jaydev Hulot, Jean-Sébastien Hajjar, Roger J. 3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs |
title | 3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs |
title_full | 3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs |
title_fullStr | 3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs |
title_full_unstemmed | 3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs |
title_short | 3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs |
title_sort | 3444 development of human engineered cardiac tissue (hect)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs |
topic | Basic/Translational Science/Team Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799095/ http://dx.doi.org/10.1017/cts.2019.23 |
work_keys_str_mv | AT stillitanofrancesca 3444developmentofhumanengineeredcardiactissuehectbasedscreeningassaytoexplorecardiaccontractilepropertiesinresponsetopharmacologicalchallengewithproarrhythmicdrugs AT turnbullirenec 3444developmentofhumanengineeredcardiactissuehectbasedscreeningassaytoexplorecardiaccontractilepropertiesinresponsetopharmacologicalchallengewithproarrhythmicdrugs AT davejaydev 3444developmentofhumanengineeredcardiactissuehectbasedscreeningassaytoexplorecardiaccontractilepropertiesinresponsetopharmacologicalchallengewithproarrhythmicdrugs AT hulotjeansebastien 3444developmentofhumanengineeredcardiactissuehectbasedscreeningassaytoexplorecardiaccontractilepropertiesinresponsetopharmacologicalchallengewithproarrhythmicdrugs AT hajjarrogerj 3444developmentofhumanengineeredcardiactissuehectbasedscreeningassaytoexplorecardiaccontractilepropertiesinresponsetopharmacologicalchallengewithproarrhythmicdrugs |